$-0.19 EPS Expected for HTG Molecular Diagnostics, Inc. (HTGM)

October 13, 2018 - By Peter Kolinski

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Logo

Analysts expect HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) to report $-0.19 EPS on November, 6.They anticipate $0.27 EPS change or 58.70 % from last quarter’s $-0.46 EPS. After having $-0.14 EPS previously, HTG Molecular Diagnostics, Inc.’s analysts see 35.71 % EPS growth. The stock increased 3.07% or $0.11 during the last trading session, reaching $3.69. About 516,664 shares traded. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has risen 112.82% since October 14, 2017 and is uptrending. It has outperformed by 97.20% the S&P500.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $104.88 million. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

Another recent and important HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news was published by Seekingalpha.com which published an article titled: “Canaccord bullish on medical diagnostic firms” on September 14, 2018.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: